Abstract
Inflammation enables human cancers and is a critical promoter of hepatocellular carcinoma (HCC). TIMP3 (Tissue inhibitor of metalloproteinase 3), a natural metalloproteinase inhibitor, controls cytokine and growth factor bioavailability to keep inflammation in check and regulate cell survival in the liver. TIMP3 is also found silenced in human cancers. We therefore tested whether Timp3 affects HCC predisposition. Remarkably, genetic loss of Timp3 protected from carcinogen-induced HCC through the immediate engagement of several tumor suppressor pathways, while tumor necrosis factor (TNF) signaling was dispensable for this protection. All wild-type mice developed HCC by 12 months, whereas HCC incidence was reduced to 33% at 12 months and 57% at 15 months in Timp3 null mice. Upon acute carcinogen treatment the deficient livers exhibited greater cytokine expression, but lower cell death and higher hepatocyte senescence. We found that precocious activation of p53, p38 and Notch preceded senescence and hepatic cell differentiation, and these events were conserved throughout tumorigenesis. Timp3-deficient mouse embryo fibroblasts also responded to carcinogen by favoring senescence over apoptosis. We conclude that Timp3 status determines p53, p38 and Notch coactivation to instruct hepatic cell fate and transformation and uncover mechanisms that are protective even within a pro-inflammatory microenvironment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
El-Serag HB . Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118–1127.
Laurent-Puig P, Zucman-Rossi J . Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778–3786.
Coussens LM, Werb Z . Inflammation and cancer. Nature 2002; 420: 860–867.
Farazi PA, DePinho RA . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674–687.
Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007; 39: 741–749.
Qi R, An H, Yu Y, Zhang M, Liu S, Xu H et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63: 8323–8329.
Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 2004; 36: 969–977.
Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R . Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006; 176: 721–725.
Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest 2010; 120: 2731–2744.
Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, Fabrizi M et al. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010; 51: 103–110.
Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009; 136: 663–72 e4.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729–733.
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281–1284.
Wisniewska M, Goettig P, Maskos K, Belouski E, Winters D, Hecht R et al. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol 2008; 381: 1307–1319.
Black RA . TIMP3 checks inflammation. Nat Genet 2004; 36: 934–935.
Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798–802.
Catasus L, Pons C, Munoz J, Espinosa I, Prat J . Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas. Histopathology 2013; 62: 632–641.
Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498–509.
Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787–1797.
Masson D, Rioux-Leclercq N, Fergelot P, Jouan F, Mottier S, Theoleyre S et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer 2010; 46: 1430–1437.
Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 2005; 85: 165–175.
Maeda S, Kamata H, Luo JL, Leffert H, Karin M . IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977–990.
Verna L, Whysner J, Williams GM . N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57–81.
Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima S . Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res 2007; 67: 11141–11146.
Mah LJ, El-Osta A, Karagiannis TC . gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24: 679–686.
Vesselinovitch SD, Mihailovich N . Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 1983; 43: 4253–4259.
Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119–132.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461–466.
Poehlmann A, Roessner A . Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract 2010; 206: 591–601.
Murthy A, Shao YW, Narala SR, Molyneux SD, Zuniga-Pflucker JC, Khokha R . Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity 2012; 36: 105–119.
Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F et al. Notch signaling controls liver development by regulating biliary differentiation. Development 2009; 136: 1727–1739.
Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 2009; 136: 2325–2333.
Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B . Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 2009; 50: 871–879.
Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379–1383.
Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 2003; 97: 3017–3026.
Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121–124.
Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000; 192: 1809–1818.
Vousden KH, Prives C . Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413–431.
Lowe SW, Cepero E, Evan G . Intrinsic tumour suppression. Nature 2004; 432: 307–315.
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656–660.
Han J, Sun P . The pathways to tumor suppression via route p38. Trends Biochem Sci 2007; 32: 364–371.
Bulavin DV, Fornace AJ Jr . p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95–118.
Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008; 14: 156–165.
Xu P, Liu J, Sakaki-Yumoto M, Derynck R . TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal 2012; 5 ra34.
Dolado I, Nebreda AR . Regulation of tumorigenesis by p38αMAP kinase. In: F Posas, AR Nebreda (eds). Topics in Current Genetics: Stress-Activated Protein Kinases.. Springer-Verlag: Berlin, Heidelberg, 2008, pp 99–128.
Hui L, Bakiri L, Stepniak E, Wagner EF . p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007; 6: 2429–2433.
Lavin MF, Gueven N . The complexity of p53 stabilization and activation. Cell Death Differ 2006; 13: 941–950.
Boggs K, Henderson B, Reisman D . RBP-Jkappa binds to and represses transcription of the p53 tumor suppressor gene. Cell Biol Int 2009; 33: 318–324.
Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T . Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 2007; 27: 3732–3742.
Mandinova A, Lefort K, Tommasi di Vignano A, Stonely W, Ostano P, Chiorino G et al. The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response. EMBO J 2008; 27: 1243–1254.
Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20: 3427–3436.
Kohler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK . Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology 2004; 39: 1056–1065.
Jeliazkova P, Jors S, Lee M, Zimber-Strobl U, Ferrer J, Schmid RM et al. Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology 2013; 57: 2469–2479.
Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013; 57: 1607–1619.
Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012; 143: 1660–1669 e7.
Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52–67.
Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD . Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249–255.
Sun H, Gulbagci NT, Taneja R . Analysis of growth properties and cell cycle regulation using mouse embryonic fibroblast cells. Methods Mol Biol 2007; 383: 311–319.
Acknowledgements
We would like to thank Dr Paul Waterhouse and Dr Razqallah Hakem for their constructive criticism of the manuscript. This work was supported by grants from the Canadian Institutes of Health Research to RK. VD was supported by the Helena H Lam and Fondation pour la Recherche Médicale fellowships.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Defamie, V., Sanchez, O., Murthy, A. et al. TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene 34, 4098–4108 (2015). https://doi.org/10.1038/onc.2014.339
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2014.339
This article is cited by
-
Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma
Scientific Reports (2020)
-
Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice
Acta Diabetologica (2019)
-
TIMPs: versatile extracellular regulators in cancer
Nature Reviews Cancer (2017)
-
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma
Scientific Reports (2017)